| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| disitamab vedotin | $50.00M | $50.00M | $50.00M | $50.00M | $400.00M | $400.00M | $400.00M | $400.00M |
| Tukysa | — | — | — | $400.00M | $205.00M | $205.00M | $205.00M | $205.00M |
| Total | $109.00M | — | — | — | — | — | — | — |
disitamab vedotin, osivelotor are derived from annual filings.